JAK抑制剂治疗急性重度溃疡性结肠炎的有效性与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入35项研究共664例急性重度溃疡性结肠炎(ASUC)患者,评估JAK抑制剂的有效性与安全性。短期(<1个月)托法替布临床应答率77.9%、结肠切除率11.5%,乌帕替尼分别为86.5%和11.2%。JAK抑制剂作为静脉糖皮质激素的辅助或挽救治疗有效且安全,两种药物结局相似。
要点
- 短期托法替布临床应答77.9%、结肠切除11.5%,乌帕替尼应答86.5%、切除11.2%
- 中期(<3个月)托法替布缓解37.3%、乌帕替尼缓解47.4%
- 不良事件:静脉血栓栓塞2.2%、主要心血管不良事件0.7%、带状疱疹3.4%
核心结论
- JAK抑制剂作为静脉糖皮质激素的辅助治疗和挽救治疗,在ASUC中有效且安全。
- 托法替布与乌帕替尼在ASUC中结局相似。
- 需要随机对照试验评估JAK抑制剂与糖皮质激素联合治疗及作为激素无应答ASUC挽救治疗的作用。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Scopus数据库至2025年12月17日。
- 共纳入35项研究、664例患者。
- 使用Joanna Briggs工具评估研究质量。
主要发现
- 短期(<1个月)托法替布临床应答率77.9%(95%CI 67.1%-86%),结肠切除率11.5%(95%CI 7.1%-18.4%)。
- 短期乌帕替尼临床应答率86.5%(95%CI 72.3%-94.1%),结肠切除率11.2%(95%CI 7.2%-16.9%)。
- 中期(<3个月)托法替布临床应答57.2%(95%CI 49.2%-64.8%)、缓解37.3%(95%CI 28.1%-47.5%)、结肠切除16.1%(95%CI 10.9%-23.1%)。
- 中期乌帕替尼临床应答56.1%(95%CI 39.3%-71.7%)、缓解47.4%(95%CI 37.6%-57.4%)、结肠切除21.2%(95%CI 15.8%-27.7%)。
- 长期(3-12个月)托法替布临床应答41.4%(95%CI 34.4%-48.8%)、缓解33.8%(95%CI 28.4%-39.5%)、结肠切除22.6%(95%CI 17.5%-28.6%);乌帕替尼临床应答35.1%(95%CI 21.1%-52.2%)、缓解37.5%(95%CI 19.1%-60.4%)、结肠切除23.4%(95%CI 17.1%-31.4%)。
关键数值与推荐
- 高剂量与标准剂量托法替布的有效性无差异。
- 不良事件:静脉血栓栓塞2.2%(95%CI 1.1%-4.7%)、主要心血管不良事件0.7%(95%CI 0.1%-10.3%)、带状疱疹3.4%(95%CI 1.9%-6.1%)。
临床怎么用
- JAK抑制剂可作为ASUC患者静脉糖皮质激素的辅助治疗或挽救治疗选择。
- 托法替布和乌帕替尼在ASUC中疗效相似,选择时需结合安全性和患者个体情况。
- 需关注静脉血栓栓塞、主要心血管不良事件和带状疱疹等不良事件。
局限性
- 纳入研究多为观察性研究,证据等级受限。
- 需要随机对照试验进一步验证JAK抑制剂在ASUC中的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Janus kinase (JAK) inhibitors have been reported to be useful in acute severe ulcerative colitis (ASUC). We performed a systematic review and meta-analysis to assess their effectiveness and safety in ASUC. METHODS: Electronic databases (PubMed, Embase, and Scopus) were searched on December 17, 2025, to identify reports about using JAK inhibitors in ASUC. We extracted data concerning clinical response, remission, colectomy, and adverse events with the use of JAK inhibitors in ASUC. Pooled clinical response rates, remission rates and colectomy were calculated at short-term (<30 days), intermediate (<3 months) and long-term (3-12 months) therapy. The quality of studies was assessed using Joanna Briggs' tools. RESULTS: A total of 35 studies (664 patients) were included. In the short term (<1 month), the pooled clinical response and colectomy rate with tofacitinib was 77.9% (95% confidence interval [CI], 67.1%-86%) and 11.5% (95% CI, 7.1%-18.4%), whereas for upadacitinib, it was 86.5% (95% CI, 72.3%-94.1%) and 11.2% (95% CI, 7.2%-16.9%), respectively. In the intermediate term (<3 months), the pooled clinical response, remission, and colectomy rates with tofacitinib and upadacitinib were 57.2% (95% CI, 49.2%-64.8%), 37.3% (95% CI, 28.1%-47.5%), 16.1% (95% CI, 10.9%-23.1%), and 56.1% (95% CI, 39.3%-71.7%), 47.4% (95% CI, 37.6%-57.4%), 21.2% (95% CI, 15.8%-27.7%), respectively. In the long term (3-12 months), the pooled clinical response, remission, and colectomy rates with tofacitinib and upadacitinib were 41.4% (95% CI, 34.4%-48.8%), 33.8% (95% CI, 28.4%-39.5%), 22.6% (95% CI, 17.5%-28.6%), and 35.1% (95% CI, 21.1%-52.2%), 37.5% (95% CI, 19.1%-60.4%), 23.4% (95% CI, 17.1%-31.4%), respectively. The adverse events reported were venous thromboembolism (2.2%; 95% CI, 1.1%-4.7%), major adverse cardiovascular events (0.7%; 95% CI, 0.1-10.3%), and herpes zoster (3.4%; 95% CI, 1.9%-6.1%). There was no difference in the effectiveness of high-dose as compared with standard-dose tofacitinib. CONCLUSIONS: JAK inhibitors are effective and safe in the treatment of ASUC as an adjunct to intravenous corticosteroids and as rescue therapy. Both tofacitinib and upadacitinib were associated with similar outcomes in ASUC. Randomized controlled trials evaluating the role of JAK inhibitors as co-therapy with corticosteroids and as a salvage therapy agent in corticosteroid non-responsive ASUC are required.
引用
- Jena A, Chatterjee A, Choudhury A, et al. Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 41690364. doi:10.1016/j.cgh.2026.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。